FINWIRES · TerminalLIVE
FINWIRES

Teva Pharmaceutical Industries Positioned for Re-Rating on Growth Drivers, UBS Says

By

-- Teva Pharmaceutical Industries (TEVA) could see further upside as its valuation re-rates, supported by "expanding branded growth" and pipeline strength following its Q1 results, UBS Securities said in a report Thursday.

The firm said confidence in the company's growth profile has improved on a broadening pipeline, including the Emalex Biosciences acquisition, and rising investor "appetite" for de-risked biopharma names, while the company is emerging as a rare mix of "affordable valuation" and branded growth potential, with easing geopolitical concerns after it flagged no "material operational impact."

The firm also highlighted "shareholder-friendly capital allocation," noting that Teva has accelerated its business development strategy and is considering potential share buybacks earlier than "previously guided."

The company's management has signaled openness to additional deals, alongside plans to reduce leverage to below 2x net debt to EBITDA by 2027 and achieve investment-grade status by 2026, according to the report.

UBS has a buy rating on Teva Pharmaceutical and raised its price target to $42 from $36.

Price: $35.15, Change: $-0.23, Percent Change: -0.65%

Related Articles

Australia

Axos Financial Fiscal Q3 Earnings, Revenue Rise

Axos Financial (AX) reported fiscal Q3 earnings late Thursday of $1.90 per diluted share, up from $1.81 a year earlier.Analysts polled by FactSet expected $2.13.Revenue in the three months ended March 31 rose to $392.2 million from $308.8 million a year earlier.Analysts surveyed by FactSet expected $372.5 million.Axos shares fell 2.5% in after-hours trading.

$AX
Insider Trading

HBT Financial Insider Sold Shares Worth $455,416, According to a Recent SEC Filing

Fred L Drake, 10% Owner, Director, Executive Chairman, on April 28, 2026, sold 15,742 shares in HBT Financial (HBT) for $455,416. Following the Form 4 filing with the SEC, Drake has control over a total of 17,270,558 common shares of the company, with 14,343 shares held directly and 17,256,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/775215/000178953026000008/xslF345X05/wk-form4_1777581363.xml

$HBT
Mining & Metals

CN Says Union Pacific-Norfolk Southern Merger Fails To Address Competitive Harms

Canadian National Railway (CNR.TO, CNI) after the close Thursday said it is reviewing Union Pacific UNP) and Norfolk Southern's (NSC) amended merger application submitted to the Surface Transportation Board (STB) and will remain "actively engaged" in this process.According to a statement, the applicants have failed to "materially improve the amended application" in ways that address the competitive harms of the merger. They have not remedied the "significant competitive harms" posed by the merger, nor have they offered any meaningful competitive enhancements as required under the board's new rules, said CN, adding that "these failures should be fatal to the application"."Given the magnitude of this transaction, the board's authority to impose conditions that protect competition and the public interest must be paramount. If Union Pacific and Norfolk Southern have set a cost cap on the conditions they're willing to accept, that's their business decision and their risk. It is not a ceiling on the board's authority, and it doesn't limit what's required in the public interest," said Olivier Chouc, CN's chief legal officer.CN Rail shares closed up C$4.66 at C$152.57 on Toronto Stock Exchange.

$CNI$CNR.TO$NSC$UNP